CONTEXT THERAPEUTICS INC (CNTX)
US21077P1084 - Common Stock
Taking everything into account, CNTX scores 3 out of 10 in our fundamental rating. CNTX was compared to 193 industry peers in the Pharmaceuticals industry. While CNTX has a great health rating, there are worries on its profitability. CNTX is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year CNTX has reported negative net income.
In the past year CNTX has reported a negative cash flow from operations.
In the past 5 years CNTX reported 4 times negative net income.
CNTX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
CNTX has a Return On Assets (-34.93%) which is comparable to the rest of the industry.
CNTX has a Return On Equity of -35.96%. This is in the better half of the industry: CNTX outperforms 63.16% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -34.93% | ||
| ROE | -35.96% | ||
| ROIC | N/A |
ROA(3y)-69.55%
ROA(5y)-231.77%
ROE(3y)-88.74%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for CNTX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The number of shares outstanding for CNTX remains at a similar level compared to 1 year ago.
CNTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 17.00 indicates that CNTX is not in any danger for bankruptcy at the moment.
CNTX has a Altman-Z score of 17.00. This is amongst the best in the industry. CNTX outperforms 90.53% of its industry peers.
CNTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 17 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 36.91 indicates that CNTX has no problem at all paying its short term obligations.
CNTX's Current ratio of 36.91 is amongst the best of the industry. CNTX outperforms 98.42% of its industry peers.
CNTX has a Quick Ratio of 36.91. This indicates that CNTX is financially healthy and has no problem in meeting its short term obligations.
CNTX has a Quick ratio of 36.91. This is amongst the best in the industry. CNTX outperforms 98.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 36.91 | ||
| Quick Ratio | 36.91 |
3. Growth
3.1 Past
CNTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 30.00%, which is quite impressive.
EPS 1Y (TTM)30%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40.54%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, CNTX will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.98% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y64.13%
EPS Next 2Y33.25%
EPS Next 3Y19.76%
EPS Next 5Y9.98%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
CNTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CNTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as CNTX's earnings are expected to grow with 19.76% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.25%
EPS Next 3Y19.76%
5. Dividend
5.1 Amount
No dividends for CNTX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CONTEXT THERAPEUTICS INC
NASDAQ:CNTX (12/20/2024, 8:03:28 PM)
After market: 1.06 +0.04 (+3.92%)1.02
-0.07 (-6.42%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners76.4%
Inst Owner ChangeN/A
Ins Owners1.45%
Ins Owner Change0%
Market Cap76.50M
Analysts82
Price Target7.52 (637.25%)
Short Float %1.09%
Short Ratio3.29
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-28.85%
Min EPS beat(2)-105.41%
Max EPS beat(2)47.71%
EPS beat(4)2
Avg EPS beat(4)-6.65%
Min EPS beat(4)-105.41%
Max EPS beat(4)48.75%
EPS beat(8)3
Avg EPS beat(8)-21.89%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.28%
PT rev (3m)-3.28%
EPS NQ rev (1m)0%
EPS NQ rev (3m)71.67%
EPS NY rev (1m)-53.64%
EPS NY rev (3m)-88.39%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.91 | ||
| P/tB | 0.91 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.91
EYN/A
EPS(NY)-0.34
Fwd EYN/A
FCF(TTM)-0.23
FCFYN/A
OCF(TTM)-0.23
OCFYN/A
SpS0
BVpS1.12
TBVpS1.12
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -34.93% | ||
| ROE | -35.96% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-69.55%
ROA(5y)-231.77%
ROE(3y)-88.74%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 73.27% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 36.91 | ||
| Quick Ratio | 36.91 | ||
| Altman-Z | 17 |
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)30%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40.54%
EPS Next Y64.13%
EPS Next 2Y33.25%
EPS Next 3Y19.76%
EPS Next 5Y9.98%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-47.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-38.79%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-15.49%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-15.76%
OCF growth 3YN/A
OCF growth 5YN/A